Supplemental Table S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• The study assesses the efficacy of zilovertamab vedotin in participants with metastatic solid tumors.
• The study population evaluation reveals critical insights into participant representativeness in a phase 2 context.
• This phase 2 study methodology focuses on detailed participant demographic assessment and treatment outcomes.
• Understanding participant representativeness is crucial for evaluating treatment efficacy and generalizability.